● In Stock
TESA / IPA Blend
≥99% Purity | HPLC Verified
$135.00
PASSED
Sterility & Endotoxins
PASSED
Net Content & Purity
Purity:
≥99%
Store at
-20°C
TESA / IPA Blend is a high-purity research compound for research use only.
Additional product information will be available soon.
50+
Published Studies
GH-axis secretagogue research
2
Active Compounds
Tesamorelin 12mg + Ipamorelin 2mg
2
Receptor Pathways
GHRH-R + GHS-R (ghrelin)
99%+
Purity Verified
HPLC tested, COA included
How the TESA / IPA Blend Works
A GHRH analog paired with a selective ghrelin-receptor secretagogue, studied across the growth-hormone axis
Tesamorelin Component
GHRH Receptor Agonism
Tesamorelin is a synthetic, stabilized analog of human GHRH(1-44). It binds and activates pituitary GHRH receptors, stimulating endogenous growth-hormone secretion while preserving the body's normal pulsatile GH release pattern — unlike exogenous GH administration.
- Selective GHRH-receptor agonism at the pituitary
- Preserves physiological pulsatile GH secretion
- Stimulates downstream IGF-1 production
Ipamorelin Component
Selective GHS-R Agonism
Ipamorelin is a pentapeptide growth-hormone secretagogue that acts on the ghrelin receptor (GHS-R1a). It is noted as the first highly selective GHS — research shows it stimulates GH release without significantly raising ACTH, cortisol, or prolactin.
- Acts on the ghrelin receptor (GHS-R1a), a GHRP-like pathway
- Highly selective for GH release among secretagogues
- Minimal effect on cortisol, prolactin, ACTH in research models
Dual-Pathway Design
Combined GH-Axis Stimulation
Pairing a GHRH analog with a ghrelin-receptor secretagogue engages two distinct pituitary pathways. Research into GHRH + GHRP combinations examines whether the two mechanisms act in a complementary fashion on growth-hormone release.
- Targets GHRH-R and GHS-R simultaneously
- Studied as a complementary, two-pathway research model
- Both components act on endogenous GH secretion, not exogenous GH
What Research Has Shown
Key findings from clinical and preclinical publications on the components
⚠️ RESEARCH NOTE
Tesamorelin is FDA-approved (as Egrifta) in a clinical pharmaceutical context; Ipamorelin is not approved for human use. This research-grade TESA / IPA blend is supplied for in vitro research only and is not intended for human or veterinary therapeutic use. Cited data refers to the individual components, not this specific blend.
Research Applications
Primary areas of investigation for the components
ENDOCRINOLOGY
GH / IGF-1 Axis Research
Both components are studied as tools for examining endogenous growth-hormone secretion and downstream IGF-1 signaling without exogenous GH.
RECEPTOR PHARMACOLOGY
GHRH-R + GHS-R Signaling
Ipamorelin was characterized as the first selective GHS; pharmacological profiling confirmed it acts via a GHRP-like (ghrelin) receptor.
METABOLIC RESEARCH
Body Composition Models
Tesamorelin's Phase III research demonstrated GH-mediated reductions in visceral adipose tissue, making it a reference GHRH-analog research model.
MUSCULOSKELETAL
Bone Mineral Content
In adult female rats, the GH secretagogues ipamorelin and GHRP-6 were shown to increase bone mineral content as measured by DXA.
Safety Profile from Research
Clinical and preclinical observations on the components
✓Tesamorelin has an FDA-approved safety profile established through Phase III trials in a clinical context.
✓Ipamorelin is notably selective — research shows it did not significantly raise ACTH or cortisol even at doses far above the GH ED50.
✓Both components act on endogenous GH secretion and preserve physiological feedback, unlike exogenous growth hormone.
✓This specific blend has not been evaluated in human trials. Research-grade TESA / IPA is for in vitro research use only.
Compound Information
Technical specifications
| Product Type | Two-peptide research blend |
| Component 1 | Tesamorelin 12 mg — GHRH(1-44) analog |
| Component 2 | Ipamorelin 2 mg — GHS pentapeptide |
| Tesamorelin Molecular Weight | 5135.8 Da |
| Ipamorelin Molecular Weight | 711.86 g/mol |
| Total Peptide Content | 14 mg per vial |
| Form | Lyophilized powder |
| Purity | ≥99% (HPLC verified) |
| Testing | Third-party HPLC, Mass Spec, Endotoxin |
| Storage (lyophilized) | -20°C for long-term stability |
| Storage (reconstituted) | 2–8°C, use within 14 days |
| COA | Included with every order |
Frequently Asked Questions
Common questions about the TESA / IPA blend
TESA / IPA is a two-peptide research blend combining Tesamorelin (12 mg) — a stabilized analog of growth-hormone-releasing hormone — with Ipamorelin (2 mg), a selective growth-hormone secretagogue that acts on the ghrelin receptor. The two compounds engage different pituitary pathways involved in growth-hormone release.
Tesamorelin activates the GHRH receptor, mimicking the body's own growth-hormone-releasing hormone. Ipamorelin activates the ghrelin receptor (GHS-R1a), a separate GHRP-like pathway. Both ultimately stimulate endogenous GH secretion, but through distinct receptors — which is the rationale for studying them together.
GHRH analogs and growth-hormone-releasing peptides act on two different receptors in the pituitary. Research into combinations examines whether engaging both pathways produces a complementary effect on growth-hormone release compared with either mechanism alone.
Yes — Ipamorelin was described in the foundational 1998 research as the first selective growth-hormone secretagogue. Studies show it stimulates GH release without significantly increasing ACTH, cortisol, prolactin, or other pituitary hormones, even at doses well above the effective dose for GH release.
Tesamorelin is FDA-approved as a pharmaceutical (Egrifta) for a specific clinical indication. Ipamorelin is not approved for human use, and this specific TESA / IPA blend is not an approved product. It is supplied strictly for in vitro laboratory research and is not for human or veterinary use.
Lyophilized blend should be stored at -20°C, protected from light and moisture. Once reconstituted with bacteriostatic water, it should be kept at 2–8°C and used within approximately 14 days to preserve the integrity of both peptides.
Sources & References
PUBMED
The GH Secretagogues Ipamorelin and GH-Releasing Peptide-6 Increase Bone Mineral Content in Adult Female Rats
2000
PUBMED
Effects of Tesamorelin on Visceral Fat and Liver Fat in HIV-Infected Patients with Abdominal Fat Accumulation
2010
JOURNAL
Growth Hormone Secretagogues: History, Mechanism of Action, and Clinical Development
2020
Published research on this compound is available through PubMed and other scientific databases.
Certificate of Analysis
| Analysis Date: | Available on request |
| Lot Number: | Batch-specific |
| Purity: | >99% (HPLC) |
Third-Party Testing
- ✓ Identity verification (Mass Spectrometry)
- ✓ Purity analysis (HPLC)
- ✓ Sterility testing
- ✓ Endotoxin screening
Storage Conditions
- Lyophilized: Store at -20°C, protected from light
- Reconstituted: Store at 2-8°C, use within 30 days
- Stability: 24 months from manufacture date when stored properly
Handling Guidelines
- Use sterile technique when reconstituting
- Allow vial to reach room temperature before opening
- Reconstitute with bacteriostatic water or sterile saline
- Avoid repeated freeze-thaw cycles
RESEARCH INSIGHTS
3D Structure
TESA / IPA Blend
This compound has been extensively studied in peer-reviewed literature. Eon Peptides provides this product exclusively for legitimate in-vitro research and analytical applications.
- • High-purity research compound
- • Full analytical documentation included
- • Third-party verification available
PRODUCT SPECIFICATIONS
LOT DATA
| Lot Number | Assigned on shipment |
| Verified Purity | >99% |
| Quantity | 5mg |
MOLECULAR DATA
| Molecular Formula | Available on request |
| Form | Lyophilized Powder |
| Appearance | White to off-white powder |
